Durability of Two-Drug Antiretroviral Regimens as Maintenance Therapy in People Living with HIV and Reasons for Switch to a Three-Drug Regimen: A Real-Life Cohort Study

Use of two-drug regimens (2DR) can reduce lifetime exposure to antiretroviral drugs while maintaining viral suppression. We aim to assess the real-life durability of 2DR in treatment-experienced people living with HIV (PLWH) who are virologically suppressed. We conducted a monocentric retrospective study in a referral center for PLWH in Northern France. PLWH who received 2DR as maintenance therapy (viral load <50 copies/mL at initiation) anytime between 1 January 2011 and 1 May 2023 were included. The duration of 2DR, reasons for and factors associated with switching to 3DR were analyzed. A total of 579 PLHIV were included. Dolutegravir (DTG) or ritonavir-boosted protease inhibitor (PI/r)-based 2DR were the most frequently prescribed regimens, respectively, in 64% and 16% of cases. Sixty-nine patients (12%) received injectable long-acting cabotegravir-rilpivirine. Reasons for initiating 2DR were mainly drug reduction (61%). Median follow-up time on 2DR was 20.4 months (IQR: 7.9–36.4) with 110 patients (19%) switching to 3DR after a median duration of 10.1 months (IQR: 2.7–26.5). Sixteen patients returned to a 3DR because of virological failure leading to one new onset of resistance-associated mutation. 2DR durability was significantly longer with the DTG-based regimen (p < 0.0001). History of CD4+ T cell count <200/mm3 (HR: 1.64, 95% CI: [1.09–2.47], p = 0.018) and number of previous antiretroviral regimen (HR: 1.92, 95% CI: [1.74–2.12], p < 0.001) were associated with a return to a 3DR. Our study showed that 2DR was a sustainable simplification strategy in a real-life setting. The return to 3DR was significantly impacted by the prescription of 2DR in patients heavily pre-treated.

• Publication year

  2025

• Venue

  AIDS Patients Care and STDs

• Publication date

  2025-11-10

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/10872914251394849PMID 41212093
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain

  2024cited by this paper
• Real‐world use of long‐acting cabotegravir and rilpivirine: 12‐month results of the inJectable Antiretroviral therapy feasiBility Study (JABS)

  2024cited by this paper
• Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV

  2023cited by this paper
• Efficacy and tolerability of dolutegravir/lamivudine versus dolutegravir/rilpivirine in switching from a three‐drug regimen based on nonnucleoside reverse transcriptase inhibitors: A retrospective cohort study

  2023cited by this paper
• Country of birth is associated with discrepancies in the prescription of two-drug regimens in successfully treated people with HIV in France

  2023cited by this paper
• Country of birth is associated with antiretroviral therapy choice in treatment-naive persons with HIV in France

  2023cited by this paper
• Virological efficacy of switch to DTG plus 3TC in a retrospective observational cohort of suppressed HIV-1 patients with or without past M184V - The LAMRES Study.

  2022cited by this paper
• Two-drug regimens for HIV treatment.

  2022cited by this paper
• OUP accepted manuscript

  2022cited by this paper
• Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.

  2020cited by this paper
• Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study

  2020cited by this paper
• Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.

  2020cited by this paper
• Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.

  2019cited by this paper
• Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice

  2019cited by this paper
• Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies.

  2018cited by this paper
• Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M)

  2017cited by this paper
• Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppression: Randomized, Open-Label, Noninferiority DU

  2017cited by this paper
• Future challenges for clinical care of an ageing population infected with HIV: a modelling study

  2015cited by this paper
• Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial.

  2015cited by this paper
• Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.

  2015cited by this paper
• Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study.

  2014cited by this paper
• [NADIS 2000, development of an electronic medical record for patients infected by HIV, HBV and HCV].

  2003cited by this paper

• No citing papers are available for this paper.